Optimum Patient Care Global (OPCG)

This sponsor has funded 17 studies across 32 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
23651 Finalised International Severe Asthma Registry (ISAR) Yes No
25489 Finalised Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide Yes Yes
30430 Ongoing Biomarker Relatability in the International Severe Asthma Registry (BRISAR) No No
31355 Ongoing The Characterization and Comparison of Eosinophilic and Non-eosinophilic Phenotypes of Severe Asthma No No
31386 Ongoing The Impact of Exacerbation Burden on Lung Function Trajectory in a Broad Asthma Population and Severe Asthma Population (Exacerbation and lung... No No
32724 Planned Biologics in severe asthma: utilization patterns, causes for discontinuation and switches No No
33582 Ongoing Impact of Initiating Biologics In Patients on Long-Term OCS Or Frequent Rescue Steroids (GLITTER) No No
38128 Finalised Effectiveness across severe asthma biologic classes (Anti-IL-5 vs Anti IgE) in patients eligible for both (FIRE) Yes No
38288 Finalised Defining and Characterizing Responders to Biologic Treatment (BEAM) Yes No
40583 Ongoing Onset of asthma in severe asthma patients (PATH) No No
43785 Planned PhEnotypic Characteristics, coMorBidities and response to thErapeutic inteRventions associated with non-type 2 asthma (EMBER) No No
43806 Finalised EffectIveness of bioloGics (by classes) in patieNts with dIfferent combination of T2 biomarkErs (IGNITE) Yes Yes
44024 Planned ImPact of comoRbidity In Severe asthMa patients (PRISM) No No
44027 Planned CLinical oUtcomes before and after biologic treatMent by bIologic class, by iNdividuAl biologic, and by subgroups of baseliNe characTeristics... No No
46088 Planned Development, validation, utility and economic assessment of a flexible, individualized risk prediction e-tool for exacerbation in patients with severe... No No
49201 Ongoing Characteristics of type 2 asthma phenotypes and oral corticosteroid (OCS) use in the International Severe Asthma Registry (ISAR) (STAR) No No
103426 Ongoing Closing the loop for Fabry disease and Pompe disease in the UK (RARE) No No

PAS by Risk Management Plan (RMP) requirement

Optimum Patient Care Global (OPCG)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.